摘要
目的:分析冠心病心绞痛(CHD-AP)患者采用美托洛尔联合曲美他嗪治疗的效果。方法:将2021年1月—2023年10月淄博市张店区房镇镇卫生院收治的CHD-AP患者72例采用双盲法随机分为单一组(采用美托洛尔治疗)、科研组(美托洛尔联合曲美他嗪治疗),各36例。比较两组疗效。结果:用药后,相较于单一组,科研组血脂水平改善幅度更大(P<0.05)。相较于单一组,科研组心绞痛发作频率较少、心绞痛持续时间较短,科研组治疗总有效率更高(P<0.05)。两组不良反应总发生率比较,无明显差异(P=0.151)。结论:CHD-AP患者采用美托洛尔联合曲美他嗪治疗的效果显著,可改善患者血脂水平,减少心绞痛发作,减轻病情、达到预期疗效,保证治疗安全性。
Objective:To analyze the effect of coronary heart disease angina pectoris(CHD-AP)patients treated with metoprolol combined with trimetazidine.Methods:72 cases of CHD-AP patients admitted to Fangzhen Town Health Hospital,Zhangdian District,Zibo City,were randomly divided into a single group(treated with metoprolol)and a scientific research group(treated with metoprolol combined with trimetazidine)by double-blind method in January 2021 to October 2023,each with 36 cases,and the efficacies of the two groups were compared.Results:After medication,compared with the single group,the improvement of lipid levels in the research group was greater than that in the combined group(P<0.05).Compared with the single group,the research group had fewer angina episodes and shorter angina duration,and the total effective rate of treatment was higher in the combined group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P=0.151).Conclusion:The treatment of CHD-AP patients with metoprolol and trimetazidine is effective,which can improve the patients'blood lipid level,reduce angina attacks,alleviate the condition,achieve the expected therapeutic effect,and ensure the safety of treatment.
作者
刘帅
Liu Shuai(Zibo City Zhangdian District Fangzhen Town Health Center,Zibo 255000,Shandong Province,China)
出处
《中国社区医师》
2025年第15期10-12,共3页
Chinese Community Doctors
关键词
美托洛尔
曲美他嗪
冠心病
稳定型心绞痛
Metoprolol
Trimetazidine
Stable angina pectoris
Coronary heart disease
